The third age of antimicrobial therapy

被引：32

作者：

Casadevall, A

机构：

[1] Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA

[2] Albert Einstein Coll Med, Div Infect Dis, Dept Microbiol & Immunol, Bronx, NY 10461 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 10期

关键词：

D O I：

10.1086/503431

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1414 / 1416

页数：3

共 18 条

[1] HUMAN MONOCLONAL-ANTIBODIES NEUTRALIZING CYTOMEGALOVIRUS (CMV) FOR PROPHYLAXIS OF CMV DISEASE - REPORT OF A PHASE-I TRIAL IN BONE-MARROW TRANSPLANT RECIPIENTS [J].

AULITZKY, WE ;

SCHULZ, TF ;

TILG, H ;

NIEDERWIESER, D ;

LARCHER, K ;

OSTBERG, L ;

SCRIBA, M ;

MARTINDALE, J ;

STERN, AC ;

GRASS, P ;

MACH, M ;

DIERICH, P ;

HUBER, C .

JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1344-1347

[2] Immune therapy for infectious diseases at the dawn of the 21st century:: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers [J].

Buchwald, UK ;

Pirofski, L .

CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (12) :945-968

[3] Crisis in infectious diseases: Time for a new paradigm? [J].

Casadevall, A .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) :790-794

[4] RETURN TO THE PAST - THE CASE FOR ANTIBODY-BASED THERAPIES IN INFECTIOUS-DISEASES [J].

CASADEVALL, A ;

SCHARFF, MD .

CLINICAL INFECTIOUS DISEASES, 1995, 21 (01) :150-161

[5] Adjunctive immune therapy for fungal infections [J].

Casadevall, A ;

Pirofski, LA .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) :1048-1056

[6] SERUM THERAPY REVISITED - ANIMAL-MODELS OF INFECTION AND DEVELOPMENT OF PASSIVE ANTIBODY THERAPY [J].

CASADEVALL, A ;

SCHARFF, MD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) :1695-1702

[7] ANTIMICROBIAL CHEMOTHERAPY [J].

JAWETZ, E .

ANNUAL REVIEW OF MICROBIOLOGY, 1956, 10 :85-114

[8] CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].

KOHLER, G ;

MILSTEIN, C .

NATURE, 1975, 256 (5517) :495-497

[9] Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis [J].

Larsen, RA ;

Pappas, PG ;

Perfect, J ;

Aberg, JA ;

Casadevall, A ;

Cloud, GA ;

James, R ;

Filler, S ;

Dismukes, WE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :952-958

[10] PRELIMINARY ASSESSMENT OF A HUMAN RECOMBINANT ANTIBODY FRAGMENT TO HSP90 IN MURINE INVASIVE CANDIDIASIS [J].

MATTHEWS, R ;

HODGETTS, S ;

BURNIE, J .

JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) :1668-1671

← 1 2 →